PHARMACEUTICALS related term(s) Drugs

Articles and editorials

Costly Oversight—Fine Print in GATT Law Could Cost Zantac Users Millions, S3582 [18AP]

Zantac Windfall, S3580 [18AP]

Bills and resolutions

Dept. of HHS: prepare and publish a consumer guide to prescription drug prices (see H.R. 3059), H2034 [8MR]

Diseases: establish a data bank of information on clinical trials and experimental treatments for all serious illnesses (see S. 2024), S9554 [2AU]

Drugs: review use of radiopharmaceuticals (see H.R. 3065), H2123 [12MR]

FDA: approval process and development of new drugs and biological products (see H.R. 3199), H3229 [29MR]

Federal Food, Drug and Cosmetic Act: certification of drugs containing insulin and antibiotics (see H.R. 3672), H6509 [18JN]

Health: development of pharmaceuticals relative to treatment for illegal drug addiction (see S. 2051), S9742 [3SE]

———regulation of pharmacists (see H.R. 3260), H3581 [17AP]

Medicare: coverage of certain antibiotics parenterally administered at home (see H.R. 4248), H11526 [27SE]

———eliminate time limitation on benefits for immunity suppressing drugs (see H.R. 3138), H2664 [21MR]

———pharmaceutical care services (see H.R. 3757), H7114 [8JY]

OPM: require annual reports to Congress on changes to Federal retiree health benefits (see S. 1759; H.R. 3462), S5093 [15MY], H5173 [15MY]

Patents: extend protection for certain pipeline drugs (see S. 2154), S11720 [28SE]

Prescription Drug Price Review Board: establish (see H.R. 3691), H6690 [20JN]

Research: reinstate reasonable pricing requirements for drugs developed with Federal funding or research and establish minimum levels of research reinvestment for drug manufacturers (see H.R. 4270), H11527 [27SE]

Tariff: HIV protease inhibitor chemicals (see S. 2021; H.R. 3977), S9554 [2AU], H9922 [2AU]

———pharmaceutical-grade phospholipids (see H.R. 4273), H11527 [27SE]

Taxation: extend certain tax provisions (see S. 1568), S1180 [9FE]

———suspension of tax on ozone-depleting chemicals used as propellants in metered-dose inhalers (see H.R. 3416), H4646 [8MY]

Letters

Changes to prescription drug policies under certain Federal retiree health benefits programs: several Members of Congress, E812 [15MY]

GATT implementation relative to generic drug industry: C. Everett Koop, S7120 [27JN]

———Carole A. Long, American Society of Tropical Medicine and Hygiene, S6597 [20JN]

———Daniel Perry, Alliance for Aging Research, S6597 [20JN]

———Eugene P. Schonfeld, National Kidney Association, S6598 [20JN]

———Joseph R. Bertino, American Association for Cancer Research, Inc., S6596 [20JN]

———Judith Simpson, United Patients' Association for Pulmonary Hypertension, Inc., S6597 [20JN]

———Nancy Sander, Allergy and Asthma Network/Mothers of Asthmatics, Inc., S6598 [20JN]

———Patti Munter, National Organization on Fetal Alcohol Syndrome, S6597 [20JN]

———Robert J. Beall, Cystic Fibrosis Foundation, S6597 [20JN]

———Sandra H. Kownacki, Autism Society of America, S6598 [20JN]

———several professors of medicine, S6596 [20JN]

———William E. Brock III, Brock Group, Ltd., S7120 [27JN]

GATT implementation relative to the generic drug industry: Cathy L. Hurwit, Citizen Action (organization), S3581 [18AP]

———Cynthia Pearson, National Women's Health Network, S3580 [18AP]

———Dixie D. Horning, S3581 [18AP]

———Generic Drug Equity Coalition, S3581 [18AP]

———Martha A. McSteen, National Committee To Preserve Social Security and Medicare, S3580 [18AP]

———Mern Horan, Consumer Federation of America, S3581 [18AP]

———Thair Phillips, Seniors Coalition, S3580 [18AP]

———Theresa Amato, Citizen Advocacy Center, S3581 [18AP]

Lists

Examples of Arkansas patents granted extensions under GATT, S7119 [27JN]

Remarks in House

Association of Food and Drug Officials: anniversary, E333 [13MR]

Dept. of HHS: prepare and publish a consumer guide to prescription drug prices (H.R. 3059), E317 [8MR]

FDA: approval process and development of new drugs and biological products (H.R. 3199), H5632-H5639 [29MY], E676 [1MY]

Health: accessibility of alternative treatments and medicines (H.R. 2019), H4115 [29AP]

———regulation of pharmacists (H.R. 3260), E558 [17AP]

Medicare: pharmaceutical care services (H.R. 3757), E1228 [9JY]

NIH: require private industry to enter into price agreements relative to the sale of drugs developed in cooperative research programs, H7335-H7337 [11JY]

OPM: require annual reports to Congress on changes to Federal retiree health benefits (H.R. 3462), E811 [15MY]

Research: reinstate reasonable pricing requirements for drugs developed with Federal funding or research and establish minimum levels of research reinvestment for drug manufacturers (H.R. 4270), E1788 [28SE]

Tariff: pharmaceutical-grade phospholipids (H.R. 4273), E1775 [28SE]

Remarks in Senate

Diseases: establish a data bank of information on clinical trials and experimental treatments for all serious illnesses (S. 2024), S9563 [2AU]

Drugs: patent protection for arthritis medication Lodine, S9457, S9458, S9463-S9466, S9469, S9499-S9501 [2AU]

FDA: regulation of prescription drug industry, S8457 [22JY], S8594-S8600, S8609-S8612 [24JY], S9336, S9337 [1AU]

———review of generic drug applications, S8546 [23JY]

GATT: implementation relative to generic drug industry, S3133, S3134 [28MR], S3215 [29MR], S3574, S3578-S3583 [18AP], S6460 [19JN], S6591-S6603 [20JN], S6827 [25JN], S7115-S7125 [27JN]

———implementation relative to generic drugs, S2038 [14MR]

Health: development of pharmaceuticals relative to treatment for illegal drug addiction (S. 2051), S9743 [3SE]

OPM: require annual reports to Congress on changes to Federal retiree health benefits (S. 1759), S5094 [15MY]

Patents: extend protection for certain pipeline drugs (S. 2154), S11720-S11722 [28SE]

———litigation relative to ranitidine, S2085 [14MR]

Tariff: HIV protease inhibitor chemicals (S. 2021), S9560 [2AU]

Taxation: extend certain tax provisions (S. 1568), S1182 [9FE]

Reports filed

Generic Drug Industry Relief: Committee on the Judiciary (Senate) (S. 1277) (S. Rept. 104-394), S12125 [1OC]

Statements

GATT Implementation Relative to Generic Drug Industry: by, S3134 [28MR]

———Michael Kantor, U.S. Trade Representative, S3215 [29MR]

Summaries

Tax Provision Extension (S. 1568), S1184 [9FE]

Texts of

S. 1568, tax provision extension, S1182-S1184 [9FE]

S. 2021, tariff on HIV protease inhibitor chemicals, S9561 [2AU]

S. 2051, Pharmacotherapy Development Act, S9744-S9746 [3SE]

S. 2154, Pharmaceutical Equity Act, S11722 [28SE]